<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="838">
  <stage>Registered</stage>
  <submitdate>12/09/2005</submitdate>
  <approvaldate>12/09/2005</approvaldate>
  <nctid>NCT00193934</nctid>
  <trial_identification>
    <studytitle>Magnetic Resonance Imaging (MRI) Staging of Cervix Cancer</studytitle>
    <scientifictitle>Prospective Study to Determine the Relationships Between Survival and FIGO Stage, Tumour Volume and Corpus Invasion in Cervical Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>TROG 04.02</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cancer of the Uterine Cervix</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Womb (Uterine or endometrial cancer)</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Cervical (cervix)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>1 - Cervical Cancer Patients

</interventions>
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Assess the prognostic significance, with respect to overall survival, of the factors, FIGO stage. Overall survival is defined as the date of registration to date of death from any cause.</outcome>
      <timepoint>End of study</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Newly diagnosed, biopsy proven carcinoma of the uterine cervix.

          2. Squamous cell, adenocarcinoma, adenosquamous or large cell carcinoma histology.

          3. FIGO Stage Ib -IVa.

          4. Maximum clinical tumour diameter recorded.

          5. MRI done within 30 days prior to registration.

          6. Intention to treat radically

          7. Treatment not yet started.

          8. Written informed consent.

          9. Available for follow-up.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Female</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Lymphoma, small cell carcinoma and melanoma histology.

          2. Previous hysterectomy

          3. Pregnancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>109</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>15/05/2014</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC</recruitmentstate>
    <hospital>Liverpool Hospital - Liverpool</hospital>
    <hospital>Calvary Mater Newcastle - Newcastle</hospital>
    <hospital>Royal North Shore Hospital - Sydney</hospital>
    <hospital>Westmead Hospital - Wentworthville</hospital>
    <hospital>Royal Brisbane Hospital - Herston</hospital>
    <hospital>North Queensland Oncology Service - Townsville</hospital>
    <hospital>Premion - Tugun - Tugun</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Peter MacCallum Cancer Centre - Melbourne</hospital>
    <postcode>1871 - Liverpool</postcode>
    <postcode>2298 - Newcastle</postcode>
    <postcode>2069 - Sydney</postcode>
    <postcode>2145 - Wentworthville</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>4810 - Townsville</postcode>
    <postcode>4224 - Tugun</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3002 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Mumbai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Tamil Nadu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Dunedin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Trans-Tasman Radiation Oncology Group (TROG)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Peter MacCallum Cancer Centre, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The researchers propose that it may be corpus invasion, rather than tumour volume per se,
      which is one of the important determinants of ultimate outcome in cervix cancer. The aim of
      the proposed prospective, multicentre study, is to confirm the results of our retrospective
      studies, specifically that corpus invasion or tumour volume or both contribute important
      prognostic information over and above that provided by the currently used International
      Federation of Gynecology and Obstetrics (FIGO) staging system. A successful outcome would
      have important implications for the staging, and management as well as the biologic
      understanding of the behaviour of cervical cancer.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00193934</trialwebsite>
    <publication>Narayan K, McKenzie A, Fisher R, Susil B, Jobling T, Bernshaw D. Estimation of tumor volume in cervical cancer by magnetic resonance imaging. Am J Clin Oncol. 2003 Oct;26(5):e163-8.
Narayan K, McKenzie AF, Hicks RJ, Fisher R, Bernshaw D, Bau S. Relation between FIGO stage, primary tumor volume, and presence of lymph node metastases in cervical cancer patients referred for radiotherapy. Int J Gynecol Cancer. 2003 Sep-Oct;13(5):657-63.
Narayan K. Arguments for a magnetic resonance imaging-assisted FIGO staging system for cervical cancer. Int J Gynecol Cancer. 2005 Jul-Aug;15(4):573-82. Review.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gerard Adams</name>
      <address>Oceania Oncology</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>